RS49836B - Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja - Google Patents

Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Info

Publication number
RS49836B
RS49836B YUP-132/00A YUP13200A RS49836B RS 49836 B RS49836 B RS 49836B YU P13200 A YUP13200 A YU P13200A RS 49836 B RS49836 B RS 49836B
Authority
RS
Serbia
Prior art keywords
alkyl
intermediates
preparing anti
cancer compounds
alkoxy
Prior art date
Application number
YUP-132/00A
Other languages
English (en)
Inventor
Shelton Richard LEHNER
Timothy Norris
Paul Dinos SANTAFIANOS
Original Assignee
Pfizer Products Inc.,
Osi Pharmaceuticals Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc.,, Osi Pharmaceuticals Inc., filed Critical Pfizer Products Inc.,
Publication of RS49836B publication Critical patent/RS49836B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Abstract

Postupak za dobijanje jedinjenja Formule I: ili njegove farmaceutski prihvatljive soli ili solvata gde su: R1 i R2 , svaki nezavisno odabrani od C1-C10alkil i C1-C10alkoksi, gde su dati alkil i alkoksi po potrebi supstituisani sa do dva supstituenta nezavisno odabrana od hidroksi i C1C6alkoksi; R15 je H, C1-C10alkil ili –(CH2)q(C6-C10aril), gde je q broj od 0 do 4; naznačen time, što obuhvata reakciju jedinjenja Formule 2.: gde su R15, R1 i R2 kao što je prethodno definisano i G je blokirajuća grupa-C(OH)R3R4; R3 i R4 su svaki nezavisno C1-C6alkil; sa alkalnim metalom ili hidroksidom alkalnog metala u rastvaraču koji obuhvata hidroksi supstituisan C1-C10alkil.
YUP-132/00A 1999-03-31 2000-03-03 Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja RS49836B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
RS49836B true RS49836B (sr) 2008-08-07

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-132/00A RS49836B (sr) 1999-03-31 2000-03-03 Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Country Status (50)

Country Link
US (1) US6476040B1 (sr)
EP (1) EP1044969B1 (sr)
JP (2) JP3420549B2 (sr)
KR (2) KR100430210B1 (sr)
CN (2) CN1215061C (sr)
AP (2) AP1265A (sr)
AR (1) AR018705A1 (sr)
AT (1) ATE348098T1 (sr)
AU (2) AU781402B2 (sr)
BG (1) BG65194B1 (sr)
BR (1) BRPI0001486B8 (sr)
CA (2) CA2427221C (sr)
CO (1) CO5160273A1 (sr)
CR (1) CR6165A (sr)
CZ (1) CZ299426B6 (sr)
DE (1) DE60032275T2 (sr)
DK (1) DK1044969T3 (sr)
DZ (1) DZ3030A1 (sr)
EA (3) EA005892B1 (sr)
EE (1) EE04589B1 (sr)
EG (1) EG22506A (sr)
ES (1) ES2278578T3 (sr)
GE (1) GEP20022653B (sr)
GT (1) GT200000037A (sr)
HK (1) HK1029790A1 (sr)
HR (1) HRP20000182B1 (sr)
HU (1) HU227698B1 (sr)
ID (1) ID25427A (sr)
IL (2) IL168036A (sr)
IS (1) IS2468B (sr)
MA (1) MA25087A1 (sr)
MY (1) MY136270A (sr)
NO (2) NO321952B1 (sr)
NZ (2) NZ503683A (sr)
OA (1) OA11335A (sr)
PA (1) PA8491901A1 (sr)
PE (1) PE20001599A1 (sr)
PL (1) PL339330A1 (sr)
PT (1) PT1044969E (sr)
RS (1) RS49836B (sr)
SG (2) SG115536A1 (sr)
SK (1) SK287339B6 (sr)
SV (1) SV2002000047A (sr)
TN (1) TNSN00064A1 (sr)
TR (1) TR200000837A2 (sr)
TW (1) TW553939B (sr)
UA (2) UA70928C2 (sr)
UY (1) UY26086A1 (sr)
YU (1) YU13200A (sr)
ZA (1) ZA200001586B (sr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
TWI304061B (en) 2000-10-20 2008-12-11 Eisai R&D Man Co Ltd Nitrogen-containing aromatic ring derivatives
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
EP2609919A3 (en) 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR20080095915A (ko) * 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
DE602006021401D1 (de) 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
ES2573931T3 (es) * 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
AU2008235274B2 (en) 2007-04-04 2013-04-18 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
EP2181099A2 (en) * 2007-08-23 2010-05-05 Plus Chemicals S.A. Crystalline forms of erlotinib hcl and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
TWI577664B (zh) 2009-01-16 2017-04-11 艾克塞里克斯公司 Ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
US8952022B2 (en) 2010-07-23 2015-02-10 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP2163546B1 (en) * 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
CZ298230B6 (cs) 1998-04-29 2007-08-01 Osi Pharmaceuticals, Inc. Anhydrát a monohydrát N-(3-ethinylfenyl)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin mesylátu

Also Published As

Publication number Publication date
HU0001353D0 (en) 2000-06-28
AU2005201494B2 (en) 2008-02-07
DE60032275D1 (de) 2007-01-25
DK1044969T3 (da) 2007-04-23
DZ3030A1 (fr) 2004-03-27
EA004654B1 (ru) 2004-06-24
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
BG65194B1 (bg) 2007-06-29
BRPI0001486B1 (pt) 2019-01-29
BR0001486A (pt) 2001-05-02
SK4442000A3 (en) 2000-10-09
CR6165A (es) 2008-10-10
SV2002000047A (es) 2002-01-23
BG104278A (en) 2001-08-31
CZ20001155A3 (cs) 2001-03-14
IL135245A0 (en) 2001-05-20
CN1215061C (zh) 2005-08-17
PE20001599A1 (es) 2001-01-18
KR100430209B1 (ko) 2004-05-03
IS2468B (is) 2008-12-15
CO5160273A1 (es) 2002-05-30
ZA200001586B (en) 2001-10-01
NO20054715L (no) 2000-10-02
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
GT200000037A (es) 2001-09-21
AR018705A1 (es) 2001-11-28
HU227698B1 (en) 2011-12-28
UY26086A1 (es) 2000-10-31
MA25087A1 (fr) 2000-10-01
EP1044969B1 (en) 2006-12-13
MY136270A (en) 2008-09-30
SG115536A1 (en) 2005-10-28
JP2003176274A (ja) 2003-06-24
CN1699350A (zh) 2005-11-23
CA2427221A1 (en) 2000-09-30
PA8491901A1 (es) 2001-12-14
UA80955C2 (en) 2007-11-26
OA11335A (en) 2003-12-10
CN1276370A (zh) 2000-12-13
UA70928C2 (uk) 2004-11-15
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
ATE348098T1 (de) 2007-01-15
ID25427A (id) 2000-10-05
YU13200A (sh) 2002-10-18
ES2278578T3 (es) 2007-08-16
AP1265A (en) 2004-03-26
NO321952B1 (no) 2006-07-24
NO20001648D0 (no) 2000-03-30
NO20001648L (no) 2000-10-02
HK1029790A1 (en) 2001-04-12
EE04589B1 (et) 2006-02-15
CA2427221C (en) 2008-09-16
JP4074509B2 (ja) 2008-04-09
HRP20000182A2 (en) 2001-04-30
NZ512818A (en) 2003-01-31
PT1044969E (pt) 2007-05-31
TW553939B (en) 2003-09-21
EE200000255A (et) 2000-12-15
EA200201244A1 (ru) 2003-04-24
GEP20022653B (en) 2002-03-25
EP1044969A3 (en) 2000-11-29
EA005892B1 (ru) 2005-06-30
CA2302965C (en) 2004-02-17
EA200000274A2 (ru) 2000-10-30
SK287339B6 (sk) 2010-07-07
AP1655A (en) 2006-09-01
DE60032275T2 (de) 2007-07-12
HUP0001353A3 (en) 2002-01-28
PL339330A1 (en) 2000-10-09
IS5411A (is) 2000-10-02
KR20020084903A (ko) 2002-11-13
NZ503683A (en) 2001-09-28
KR100430210B1 (ko) 2004-05-03
JP2000290262A (ja) 2000-10-17
TR200000837A2 (tr) 2000-11-21
BRPI0001486B8 (pt) 2021-05-25
US6476040B1 (en) 2002-11-05
EA200000274A3 (ru) 2003-02-27
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
JP3420549B2 (ja) 2003-06-23
SG121687A1 (en) 2006-05-26
KR20010014658A (ko) 2001-02-26
CA2302965A1 (en) 2000-09-30
HUP0001353A2 (hu) 2001-05-28
AU2005201494A1 (en) 2005-05-05
AU781402B2 (en) 2005-05-19
CN100351242C (zh) 2007-11-28
CZ299426B6 (cs) 2008-07-23
EA200201245A1 (ru) 2003-04-24
EA005561B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
RS49836B (sr) Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
RS53569B1 (sr) Nova jedinjenja i kompozicije, te postupci za upotrebu
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
RS50087B (sr) Pirolo (2,3-d) pirimidin jedinjenja
RS51647B (sr) Jedinjenja biaril etar uree
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
WO2003039451A3 (en) Thiazole pyridazinones as adenosine antagonists
ME01311B (me) N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora
TW200714674A (en) Near-infrared absorbing material and use thereof
FI923017A (fi) Farmakologiskt verksamma hydrazinderivat och foerfarande foer deras framstaellning
ES431058A1 (es) Procedimiento para la preparacion de nuevos n-(metoximetil - furilmetil)-6, 7-benzomorfanos y -morfinanos.
SE7602122L (sv) Nya piperazinyliminorifamyciner och sett att framstella desamma
NO20001871L (no) Nye 3,6-hemiacetaler fra klassen 9a-azalider
NZ513594A (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
WO2006012490A3 (en) Ketogenic saccharides
CA2071224A1 (en) Quinoline derivatives, their production and use
MY8600428A (en) New arylamine derivatives process for their preparation and their use as microbicides
YU52498A (sh) UPOTREBA 2-ARILBENZO (b) TIOFENA ZA DOBIJANJE LEKA
HRP20020440B1 (en) 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
RS49829B (sr) Postupak i intermedijeri za proizvodnju piridin-2,3-dikarboksilat jedinjenja
DK0968189T3 (da) Fremgangsmåde til fremstilling af nicotinsyrer
HRP20000027B1 (en) Process for the preparation of alkoxyfuranoneamine derivatives, compounds obtained by this process, and the use of these compounds
YU74501A (sh) Sinteza 3-amino-3-aril propionata
HRP20070518T5 (en) DERIVATIVES OF 4-OXO-4,6,7,8-TETRAHYDROPYRROLO-1,2-a PYRAZINE-6-CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP0465659A4 (en) Piperazine compound, production thereof, and medicinal use thereof